Viridian Therapeutics (VRDN) Corporate presentation summary

Strategic vision and market opportunity

• Aims to lead in autoimmune diseases, starting with thyroid eye disease (TED), targeting unmet needs and expanding the treated patient population.

• TED market is valued at ~$2B annually, with low penetration and no subcutaneous options currently available.

• Recent global approvals and limited competition set the stage for new entrants and growth.

Product pipeline and clinical milestones

• Veligrotug (IV) and elegrobart (SC) are lead candidates for TED, both showing robust efficacy and safety in pivotal phase 3 trials.

• Veligrotug has a PDUFA target date of June 30, 2026, and is launch-ready with Breakthrough Therapy and Priority Review designations.

• Elegrobart is positioned to be the first subcutaneous autoinjector for TED, with BLA submission anticipated in Q1 2027.

• Pipeline includes anti-TSHR and FcRn inhibitors, with IND submissions and clinical data expected in 2026.

Clinical trial results and product profiles

• Veligrotug demonstrated rapid, durable proptosis and diplopia responses in both active and chronic TED, with 70% of responders maintaining effect at 52 weeks.

• Elegrobart met primary and secondary endpoints in both REVEAL-1 (active TED) and REVEAL-2 (chronic TED), showing rapid onset, IV-like efficacy, and strong tolerability.

• Both products offer shorter, more convenient dosing regimens compared to current therapies, with elegrobart enabling at-home administration.